62. Recombinant tissue plasminogen activator in neonates: Potential risks and benefits

62. Recombinant tissue plasminogen activator in neonates: Potential risks and benefits

Life-threatening intra-cardiovascular thrombi are rare in neonates. Recombinant tissue plasminogen activator (rTPA) which stimulates fibrinolysis, is used in adults to facilitate thrombus resolution. Its use along with heparin in neonates remains controversial because of potential risk of serious bl...

Full description

Bibliographic Details
Main Authors:	Milad Elsegaier, M.O. Galal, Muhammad A. Khan, Tarek Momenah
Format:	Article
Language:	English
Published:	Saudi Heart Association 2015-10-01
Series:	Journal of the Saudi Heart Association
Online Access:	http://www.sciencedirect.com/science/article/pii/S1016731515003024

Similar Items

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
by: Nancy Kunjukunju, et al.
Published: (2011-02-01)

Subconjunctival and topical application of recombinant tissue plasminogen activator in rabbits
by: José Ricardo de Abreu Reggi, et al.

Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
by: Raczyńska D, et al.
Published: (2015-11-01)

12. Percutaneous balloon angioplasty for critical aortic coarctation in newborns and infants: Is it still a valid option?
by: Shehla Jadoon, et al.
Published: (2015-10-01)

Tissue plasminogen activator for a rare case of neonatal empyema
by: A.B. Montgomery, et al.
Published: (2020-03-01)

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
by: Małgorzata Dybowska, et al.
Published: (2020-08-01)

Long-term stability of recombinant tissue plasminogen activator at -80 C
by: Sperling Matthew, et al.
Published: (2009-06-01)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
by: Yang HW, et al.
Published: (2012-10-01)

The Outcome of Treatment with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
by: Alia Saberi, et al.
Published: (2021-07-01)

Intravenous thrombolysis with recombinant tissue plasminogen activator in vascular warning syndromes
by: A. González Hernández, et al.
Published: (2014-07-01)

61. Recanalization of patent ductus arteriosus after spontaneous closure
by: El-Segaier Milad, et al.
Published: (2015-10-01)

Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
by: Yi-Ju Tseng, et al.
Published: (2020-01-01)

Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator
by: Sanjith Aaron, et al.
Published: (2020-12-01)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
by: Ong CT, et al.
Published: (2017-05-01)

Studies on the bolus administation of recombinant tissue plasminogen activator in acute myocardial infarction
by: Purvis, John Arthur
Published: (1992)

Successful use of recombinant tissue plasminogen activator (r-TPA) for management of chylothorax associated with central venous thrombosis after neonatal cardiac surgery
by: Sameh R Ismail, et al.
Published: (2015-06-01)

The hepatic clearance of recombinant tissue-type plasminogen activator decreases after an inflammatory stimulus
by: M.R. Nagaoka, et al.
Published: (2000-01-01)

Use of the Recombinant Tissue Plasminogen Activator in the Management of Complex Infected Intraperitoneal Fluid Collection
by: Aibek E. Mirrakhimov, et al.
Published: (2019-01-01)

Recombinant tissue‐type plasminogen activator treatment in an extremely low birth weight infant
by: Tomonori Kurimoto, et al.
Published: (2021-05-01)

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
by: Jordan Gainey, et al.
Published: (2018-09-01)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
by: Sadeghi-Hokmabadi E, et al.
Published: (2016-10-01)

Optimizing production of recombinant tissue plasminogen activator in non-pathogenic Leishmania by two genetic constructs
by: Hemayatkar M, et al.
Published: (2011-02-01)

Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study
by: Zenz, Werner, et al.
Published: (2004)

Predictors of intracerebral hemorrhage in acute stroke patients receiving intravenous recombinant tissue plasminogen activator
by: Vijay Chenna, et al.
Published: (2018-01-01)

Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series
by: Sylves Patrick, MD, et al.
Published: (2018-10-01)

Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
by: Yonge Liu, et al.
Published: (2021-03-01)

Comparing the Quality of Life in Patients with Stroke Under the Treatment with and Without Recombinant Tissue Plasminogen Activator
by: Zahra Goudarzi, et al.
Published: (2019-06-01)

Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale
by: Djuro Kosanovic, et al.
Published: (2021-03-01)

The role of leukoaraiosis on outcomes and recombinant tissue-plasminogen activator-related symptomatic intracerebral hemorrhages in acute stroke
by: Ezgi Sezer Eryildiz, et al.
Published: (2020-01-01)

The Effect of Recombinant Tissue Plasminogen Activator (r-tPA) on Quantitation of Neutralising Anti-Streptokinase Antibodies
by: Afshin Afshari R. Elizbeth Holme
Published: (2004-09-01)

Intravitreous Recombinant Tissue Plasminogen Activator and Gas to Treat Submacular Hemorrhage in Age-Related Macular Degeneration
by: San-Chang Tsai, et al.
Published: (2003-12-01)

Streptokinase versus recombinant tissue-type plasminogen activator for thrombolysis of mechanical prosthetic heart valve thrombosis
by: Nilkanth Chandrakant Patil, et al.
Published: (2016-01-01)

Magnetically Guided Recombinant Tissue Plasminogen Activator for Target Thrombolysis in a Rat Ischemic Stroke Model
by: Hsiao Pin Lin, et al.
Published: (2009)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
by: T. Grinenko, et al.
Published: (2019-12-01)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
by: Nicholas G Kounis, et al.
Published: (2011-01-01)

Successful thrombolytic therapy with recombinant tissue-type plasminogen activator for massive pulmonary embolism -A case report-
by: Min Soo Kim, et al.
Published: (2010-07-01)

Does intravenous administration of recombinant tissue plasminogen activator for ischemic stroke can cause inferior myocardial infarction?
by: Mostafa Almasi, et al.
Published: (2016-06-01)

Stability of Recombinant Tissue Plasminogen Activator at &#8722;30 &#176;C over One Year
by: Abdulmalik Alkatheri
Published: (2013-01-01)

Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
by: Sharma S, et al.
Published: (2008-01-01)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
by: Chapman SN, et al.
Published: (2014-02-01)